🇮🇳

India Market Intelligence

· daily

India Debt Bond Securities SEBI Regulatory Filings — October 23, 2026

The 15 filings in this India Debt Securities stream are almost entirely routine debt-market disclosures dated 23 October 2026: NCD allotments and interest/redemption certificates, Commercial Paper issuances and redemptions, CFO use-of-proceeds certificates, and listing approvals. The only filing with substantive financial data is Kotak Mahindra Prime's H1 FY27 results, which show total income up about 8.5% and profit after tax up about 12.5% year-on-year for the half, but a sharp sequential fall in Q2 PAT (about 32% QoQ) and a drop in Q2 total comprehensive income driven by an equity-instrument fair-value loss in OCI. Debt outstanding at Kotak rose to about Rs 29.5 lakh crore from Rs 26.9 lakh crore since 31 March 2026, indicating continued reliance on market borrowing. Navi Finserv was the most active issuer, paying monthly NCD interest on three series on 21-22 October and redeeming Rs 13 crore of Commercial Paper at maturity, with no reported delays. New issuance activity was visible across the mid-market: PNB Housing allotted Rs 253.65 crore of 8.4552% secured NCDs maturing in 2031, A.K. Capital Services approved Rs 50 crore of CPs, and Tata Communications placed Rs 300 crore of one-month CP at 6.75%. Regency Fincorp dominated the governance-related disclosures, with its Q2 results, a Rs 40 crore NCD issuance, and BSE listing approval, though its filing references five private-placement tranches totaling Rs 200 crore with 13-14% coupons that are not reconciled to the single Rs 40 crore issuance in the Board outcome. Overall, there were no signs of payment stress, and the market backdrop implied by coupons and tenors is stable with issuers accessing funding at normal spreads.

1 high priority 14 medium 15 total filings
· daily

India Healthcare Pharma Policy Regulatory Filings — October 23, 2026

The India Healthcare Policy stream for 2026-10-23 contains a single enriched filing, from Jupiter Life Line Hospitals Limited, a hospital operator rather than a pharma or policy-focused entity, so it sits within the healthcare-hospital scope of the digest. Its Q2 FY27 investor presentation shows a split story: top-line momentum with consolidated total income up 16.0% YoY to Rs 456.5 Cr and EBITDA up 15.9% YoY to Rs 106.9 Cr, but PAT fell 1.7% YoY to Rs 56.4 Cr and H1 PAT declined 7.4% YoY. The gap is explained by Dombivli ramp-up losses, higher marketing spend, depreciation and a sharp rise in finance costs (Q2 up roughly 77% YoY to Rs 13.8 Cr; H1 up about 66% to Rs 26.7 Cr) tied to debt-funded capex. Gross margin slipped marginally to 81.1% from 81.3%, signalling limited pricing pressure but rising operating drag. The Board's approval to acquire leased land for the Pune South hospital at Rs 150 Cr (Rs 100 Cr net cash outflow after a Rs 50 Cr deposit) is the key capital-allocation development and makes leverage and capex execution the central investor question. Overall the signal is mixed: healthy revenue and EBITDA expansion offset by margin-of-profit erosion and rising leverage costs.

1 medium 1 total filings
· daily

India SEBI Regulatory Enforcement Actions — October 23, 2026

This India Regulatory Enforcement Actions stream covers two filings dated 2026-10-23, and only one falls within its stated scope. Setco Automotive's Regulation 33 disclosure is squarely within scope because it documents an active SEBI enforcement matter: a Quasi-Judicial Authority order dated 5 February 2026 restraining promoter directors from dealing in securities for two years, which the Securities Appellate Tribunal stayed on 7 May 2026 with the next hearing in November 2026. Its headline Q1 FY27 standalone profit of ₹20,530 Lakhs is almost entirely a ₹21,428 Lakhs non-operating investment gain, while standalone revenue fell to ₹29 Lakhs from ₹38 Lakhs YoY; consolidated revenue rose about 12% YoY to ₹5,290 Lakhs, but continuing operations swung to a ₹661 Lakhs loss from ₹411 Lakhs a year earlier, so the profit reflects discontinued operations. The auditors' qualified review conclusion, covering unreviewed subsidiaries that hold ₹11,987 Lakhs of assets and a going-concern flag at Lava Cast, is a material governance and disclosure concern. Cian Healthcare's NCLT-driven cessation of Dr. Smiths Biotech is an insolvency-resolution event under the IBC rather than a SEBI, MCA prosecution, or RBI enforcement action, and is therefore treated as out of scope. No forward-looking guidance, insider transaction, or capital allocation data was provided for either filing, so the signals below rest on reported period comparisons and the enforcement record.

2 high priority 2 total filings
· daily

BSE Bankex Banking Sector Regulatory Filings — October 23, 2026

Across the ten BSE BANKEX constituent filings dated 23 October 2026, the dominant theme is a sharp year-over-year earnings recovery at IndusInd Bank and ICICI Bank alongside margin pressure and mix deterioration. IndusInd swung from a Q2 FY26 loss to a consolidated net profit of ₹1,242 crore, with Gross NPA down to 2.73% from 3.60%, but NIM compressed to 3.23% from 3.32% (3.57% QoQ per the investor deck), CRAR fell to 16.59% from 17.10%, and LCR slipped to 127% from 132%. ICICI Bank delivered 20.1% YoY PAT growth to ₹14,843 crore and 17.7% NII growth, yet NIM fell to 4.18% from 4.36% and gross NPA additions rose to ₹4,833 crore, with CASA growth lagging deposit growth. Punjab National Bank showed credit and profit growth (advances +14.7% YoY, net profit +12.8% YoY, net NPA 0.25%) but disclosed treasury income of ₹753 crore versus ₹1,700 crore a year earlier and a corporate slippage in road/infrastructure, meaning headline asset quality is flattered by a single ₹798 crore write-back. Governance and personnel filings (board appointments at IndusInd and Bank of Baroda, a 14-name SMP expansion at IndusInd) are routine and carry no financial signal. The Canara Bank AT1 redemption was executed cleanly, removing a call-option overhang on that issue.

1 high priority 9 medium 10 total filings
· daily

BSE Metal Sector Regulatory Filings — October 23, 2026

Across the 11 filings for the India BSE METAL stream (all dated 2026-10-23), the dominant theme is strong year-over-year top-line growth paired with sequential margin and profit softness. JSW Steel reported Q2 FY27 consolidated revenue of Rs. 54,486 crore (up 31% YoY on a proforma basis) but EBITDA margin contracted to 18.3% from 19.8% as coking coal costs rose and realisations fell, though net debt fell to Rs. 44,482 crore and net gearing improved to 0.39x. Jindal Steel reported consolidated revenue of Rs. 16,678.54 crore (up 42.6% YoY) while sequential PAT declined and consolidated net debt stood at Rs. 14,786 crore at 1.51x net debt/EBITDA, with an impairment exposure on its Mauritius subsidiary. Hindustan Zinc is the standout performer, with record Q2 FY27 revenue of Rs. 15,093 crore (up 77% YoY), EBITDA margin of 62%, net profit up 142% YoY, and full-year cost of production guidance cut to $825-850/t. Capacity expansion is the other major thread: JSW Steel's Board approved a Rs. 7,500 crore equity contribution for a 5 MTPA Sambalpur expansion starting April 2027, while Jindal Steel's disclosures centre on seasonal weakness and higher coking coal costs. Jindal Stainless and the Jindal Steel option-grant filing are administrative and low-materiality.

6 high priority 5 medium 11 total filings
· daily

BSE Auto Sector Regulatory Filings — October 23, 2026

Across the six BSE AUTO filings dated 23 October 2026, the dominant theme is a sharp top-line rebound at Tata Motors (standalone revenue up 42% YoY to ₹23,930 Cr and standalone PAT swinging to ₹2,138 Cr from a ₹1,021 Cr loss), but the quality of that growth is mixed: standalone EBIT margin fell 50 bps YoY to 9.7% on commodity headwinds, ILMCV domestic market share slipped 170 bps QoQ to 36.3%, and consolidated PAT dropped to ₹1,254 Cr from ₹2,556 Cr in the prior quarter after a ₹708 Cr fair-value loss. Balance-sheet deleveraging is a clear positive, with standalone debt-equity improving to 0.13 from 0.54 and finance costs falling to ₹52 Cr from ₹186 Cr. The pending ~₹42,561 Cr all-cash Iveco tender offer (closing 26 October 2026) is the most material event in the set and shifts the investment debate toward execution and integration risk. Governance and event risk is concentrated at Schaeffler India, where the CEO's custody matter was de-escalated (non-bailable charge dropped, bail granted, further investigation stayed) but the formal interim order remains outstanding. Exide's filing is routine compliance with no financial content, and the Tata Motors Passenger Vehicles board/results notice sets the next catalyst date at 13 November 2026.

2 high priority 4 medium 6 total filings
· daily

BSE FMCG Sector Regulatory Filings — October 23, 2026

Six filings were received for the BSE FMCG stream dated 2026-10-23; all six issuers are S&P BSE FMCG constituents, so none were excluded. The most material quantitative development is Colgate-Palmolive (India)'s Q2 FY27 print: net sales rose 12.2% YoY to Rs. 1,691.6 Crore (6.3% QoQ), marking a second consecutive quarter of double-digit domestic growth, but PAT grew only 4.3% YoY to Rs. 341.6 Crore and was flat-to-down QoQ (-0.4%), implying margin pressure despite top-line momentum (management cited 5.5% PAT growth excluding one-offs). Colgate also declared a Rs. 24 per share First Interim Dividend with a November 2 record date and November 19 payment, and its PerioGard range became the first in India to receive the ISP Seal of Acceptance. Varun Beverages and Britannia have both entered quarterly-results windows, with board meetings on October 30 and November 5 respectively, and insider trading windows (Varun extended to November 1) are closed, so the near-term information flow will be driven by these results and dividend decisions. Godrej Consumer Products' Indonesian insecticide plant entered commercial production on October 23, adding export capacity without quantified financials. Tata Consumer Products flagged investor-conference appearances on November 16-18 with an explicit no-UPSI commitment, a low-materiality event. Overall, the sector narrative is top-line resilience paired with profitability pressure, with the upcoming Varun and Britannia results as the key tests of whether that pattern is broad-based.

6 medium 6 total filings
· daily

BSE Pharma Sector Regulatory Filings — October 23, 2026

Across the 14 filings for the BSE PHARMA stream (all dated 23 October 2026), the dominant theme is a sharp divergence between headline top-line growth and bottom-line pressure. Torrent Pharmaceuticals' Q2 FY27 revenue rose 51% YoY to Rs. 4,979 crore, but largely through the J.B. Chemicals consolidation (Rs. 1,086 crore), while base business grew 18% and PAT fell 9.6% YoY as finance costs (Rs. 300 crore vs Rs. 48 crore) and D&A (Rs. 609 crore vs Rs. 204 crore) rose sharply. Dr. Reddy's Laboratories shows the same pattern at a larger scale: Q2 FY27 revenue was down 1.5% YoY but up 7.4% QoQ, consolidated net profit fell 31-36% YoY, gross margin slipped to 52.1% from 54.7%, and the company is still managing a semaglutide API quality issue, FDA Form 483 observations and a Form 2953 records assessment, with North America base business (ex-lenalidomide) growing double digits. Positive regulatory and clinical news came from Cipla (zero Form 483 observations at the InvaGen Hauppauge site) and Sun Pharma (UNLOXCYT long-term data at ESMO 2026 on 24 October). The filing flow is dominated by earnings-calendar governance items (Glenmark results 5 November, Max Healthcare results 30 October, trading-window closures) that set up a dense results cycle over the next two weeks, and a governance note on Dr. Reddy's related-party appointment of Akhil Ravi effective 13 November 2026. Overall, the sector is showing operating resilience in branded and emerging markets alongside margin and cost pressure from integration, finance costs and US generic headwinds.

4 high priority 10 medium 14 total filings
· daily

BSE Realty Real Estate Sector Regulatory Filings — October 23, 2026

Across nine filings for the BSE REALTY stream dated 2026-10-23, the dominant story is a sharp divergence between top-line momentum and earnings quality at Godrej Properties, the sector's most data-rich name in this batch. Godrej's Q2 FY27 consolidated revenue from operations reached ₹1,935.17 Cr versus ₹740.38 Cr a year earlier (~+161% YoY), yet consolidated PAT fell ~64% YoY to ₹145.47 Cr and half-year PAT fell ~51% to ₹494.85 Cr, driven by lower other income (₹636.56 Cr vs ₹1,209.67 Cr), a swing in JV/associate results, and a sharp rise in deferred tax. Operationally, Q2 bookings were ₹8,008 Cr (down 6% YoY, 7% QoQ) while H1 bookings hit a record ₹16,659 Cr (+7% YoY), with collections up 31% YoY to ₹5,318 Cr and sustenance sales at a record ₹5,054 Cr, signalling a cash-generation pivot ahead of launch-led growth. Management guides H2 FY27 bookings of ₹22,500-25,000 Cr, collections of ₹15,000 Cr and operating cash flow of ₹7,000 Cr, and targets positive free cash flow and a 20% reported ROE in FY28, but Q2 launches were only one-third of the expected annual pipeline, so delivery against this guidance is the key test. Peers and other names in the stream were largely procedural: Birla Estates announced a ~₹1,650 Cr Pune project, Phoenix Mills scheduled its results board meeting for October 30, and Oberoi and Godrej filed call transcripts and recordings, with no quantitative data disclosed in those procedural filings. Consolidated net worth rose to ₹19,358.58 Cr, a useful balance-sheet cushion against the earnings volatility.

2 high priority 7 medium 9 total filings
· daily

India BSE NSE Trading Suspension Orders — October 23, 2026

This Indian trading suspensions and delistings stream covers two filings, both categorized as regulatory action, and both carry mixed sentiment. Cian Healthcare's subsidiary Dr. Smith Biotech ceased to be a subsidiary on October 23, 2026 after an NCLT-approved resolution plan extinguished its equity, a deconsolidation event with negligible P&L impact (0.03% of FY26 total income) but a 115.63% reduction in consolidated net worth. Setco Automotive's quarterly profit was almost entirely a one-time ₹21,428 Lakhs investment gain tied to the SASPL divestment, masking continuing-operations losses that widened from ₹411 Lakhs to ₹661 Lakhs YoY, while consolidated revenue grew roughly 12% YoY to ₹5,290 Lakhs. The common thread is that headline earnings and balance sheet figures are being distorted by non-recurring corporate actions, so investors should look through reported profit to underlying operating trends. Setco also carries heavier regulatory overhang: a qualified auditor review conclusion, a going-concern flag at Lava Cast, and a SEBI order restraining promoter directors from dealing in securities that is stayed pending a November 2026 SAT hearing. Overall, the stream points to governance and disclosure quality as the key differentiator for these names.

2 high priority 2 total filings
· daily

India NCLT Insolvency Resolution Filings — October 23, 2026

Six Indian insolvency and NCLT-linked filings dated 23 October 2026 were reviewed; all six fall within the stream's focus on IBC proceedings, NCLT orders, and resolution processes, so none are excluded. The filings carry no period-over-period financial figures, insider transactions, or capital allocation data, so the enriched quantitative fields are largely empty and the analysis rests on process milestones and timelines rather than financial trends. The dominant theme is procedural drag: VAS Infrastructure has now extended its EoI window twice (to 27 October) and pushed the final plan deadline to 7 December, signalling limited prospective-applicant response on its Borivali West asset. Unitech International's 17th CoC meeting disclosure came 11 days after the scheduled date and reports no outcome. Arisinfra Solutions has two parallel NCLT-ordered meetings (equity shareholders and secured creditors) on 25 November 2026 to approve an amalgamation of its wholly owned subsidiary, the most concrete value-relevant event in the set. Talwalkars Better Value Fitness has a 28 October board meeting on share capital reduction and preferential issuance tied to NCLAT and NCLT orders, but no financials are disclosed to size the impact.

6 high priority 6 total filings
· daily

India Monetary Policy RBI MPC Decisions — October 23, 2026

Six RBI-related filings dated October 23, 2026 were reviewed for the India Monetary Policy & Rate Changes stream, though none of them actually announce a policy rate change despite the 'Rate Change' classification. The dominant themes are regulatory tightening of bank capital and operational risk frameworks (leverage ratio standard and Second Amendment on operational risk, effective April 1, 2027), and a tight-but-managed liquidity regime, with net absorption of ₹1,07,990 crore on October 22 and a repo rate of 5.54% under the variable rate repo. Macro data points are mixed: forex reserves fell ₹1,76,258 crore over the week but remain up ₹2,92,298 crore since end-March 2026, bank deposits grew 16.7% YoY and credit grew 18.2% YoY, and headline CPI edged up in September 2026. The October RBI Bulletin's transmission data (125 bps cumulative cut, fresh-lending WALR down 93 bps) suggests monetary easing has largely passed through to new lending. Market implication: banks face higher capital and operational-risk compliance costs, while the rate environment supports credit demand; sovereign and state bond supply (₹23,300 crore auction on October 27) will be the near-term supply test. No company-specific earnings or insider data is present, so the analysis is regulatory and macro in nature.

6 high priority 6 total filings
· daily

India Sector Consolidation Regulatory Filings — October 23, 2026

This digest covers 25 Indian regulatory filings dated 23 October 2026 tracking M&A, scheme of arrangement, open offer and consolidation activity. The dominant theme is intra-group consolidation: multiple wholly owned subsidiary amalgamations (Heritage Foods, Newgen Software, Rudra Ecovation/Shiva Texfabs now effective, Siemens Rail Automation, Veefin step-down subsidiaries, Cyber Media) that simplify structures and cut compliance costs rather than add market concentration. The most material external-growth developments are JSW Steel's Rs 7,500 crore JJSL Sambalpur expansion (8/10, from April 2027), Sancode's USD 20.2 million Cirtek OSAT acquisition (CEC FY25 turnover up ~15% to USD 26.62 million), and Aeroflex's move to 51.01% control of Stilonn to enter AI Infra/Data Centre. Period-over-period data is mixed: Newgen's Q2 FY27 consolidated revenue rose about 18% YoY to Rs 42,223 lakh, Jupiter Life Line's standalone quarterly profit fell roughly 38% YoY despite a stronger half-year, and Info Edge's target Bijnis shows volatile turnover (down 14.1% in FY26) alongside an unusually high profit-to-turnover ratio. Several small, non-control stake purchases (ASI Industries, Maithan Alloys, Relaxo) are disclosure-driven rather than strategic, and the stream's scope has been applied to in-scope M&A and consolidation filings only.

14 high priority 11 medium 25 total filings
· daily

BSE IT Technology Sector Regulatory Filings — October 23, 2026

Across the 18 BSE IT constituent filings for the period, the dominant theme is strong top-line momentum in mid-caps (Coforge, Persistent, Oracle Financial Services) set against margin and earnings quality pressure in the large caps. Coforge is the standout: revenue rose 53.6% YoY in INR (40.1% in USD) to ₹61,708 Mn, EBIT grew 67.8% to ₹9,847 Mn, and FY27 EBIT margin guidance was lifted from 15.5% to 16.0% with a ~17% next-year target, though the gain is flattered by the Encora acquisition and standalone professional charges surged to ₹14,601 Mn, cutting standalone PAT 42.0% YoY. Infosys delivered a mixed Q2 FY27: revenue rose 10.7% YoY in INR but only 1.5% in constant currency, FY27 CC growth guidance was trimmed to 1-2%, free cash flow fell 8.1% YoY and other income net of finance cost fell 16.3%, while margin guidance of 20-22% was retained. Persistent Systems grew revenue 20% YoY in USD but reported PAT fell 25.4% on Nagarro deal costs, and Oracle Financial Services' headline growth is largely a one-time license effect (QoQ revenue down 44.4%). Hi-Tech vertical weakness (Infosys -17.5% YoY) and rising interest and FX costs are recurring cautionary threads.

7 high priority 11 medium 18 total filings
· daily

India Technology Sector Merger & Acquisition Filings — October 23, 2026

This digest covers a single filing from Newgen Software Technologies Limited, a technology/software company squarely within the India Tech M&A stream scope. The filing combines strong top-line momentum with a pending internal Scheme of Arrangement. Consolidated revenue from operations for Q2 FY27 reached ₹42,223.06 Lakh versus ₹35,748.37 Lakh in the prior-year quarter, approximately +18% YoY, and net profit rose to ₹8,688.20 Lakh from ₹6,282.11 Lakh in the comparison quarter. Sequentially, however, revenue growth was more modest, and total expenses rose to ₹32,352.72 Lakh from ₹31,084.08 Lakh, with other expenses up to ₹12,172.82 Lakh from ₹11,067.76 Lakh, indicating some cost pressure. The Scheme of Arrangement amalgamating wholly owned subsidiary Newgen Computers Technologies Limited into the parent, with an appointed date of April 1, 2026, is an internal consolidation rather than an external acquisition, and it remains subject to shareholder, creditor and NCLT approvals. Auditor review conclusions were unmodified on both standalone and consolidated statements, supporting reporting reliability. The overall picture is of a growing software business with healthy profitability, where the main near-term watch items are the restructuring approval path and whether cost growth moderates against revenue momentum. Because only one filing is in the digest, portfolio-level or cross-company trend conclusions are limited.

1 high priority 1 total filings
· daily

BSE Sensex 30 Stocks Regulatory Filings — October 23, 2026

Across the 14 filings for the BSE SENSEX 30 stream dated 23 October 2026, the dominant theme is a sharp divergence between headline growth and underlying quality. Bajaj Finance and ICICI Bank both delivered strong profit growth (PAT +29% and +20.1% YoY respectively) but flagged rising stressed assets or margin pressure, with ICICI's NIM falling to 4.18% from 4.36% QoQ and Bajaj's Stage 2/3 assets rising INR 1,601 crore. Infosys reported INR-denominated revenue growth of 10.7% YoY, but constant-currency growth of only 1.5% YoY, a cut to FY27 revenue guidance to 1%-2% CC growth, a 17.5% YoY decline in Hi-Tech revenue, and a 23% YoY drop in other income net of finance cost, so the headline beat flatters the operating trend. Capital returns and governance remained routine, with Infosys declaring a ₹26 interim dividend (+13% YoY, record date 3 November 2026), NTPC's board meeting on 31 October 2026 with trading window closed, and Titan's earnings call on 5 November 2026. Portfolio-level patterns include a consistent 'quality of earnings' debate (CASA mix pressure at ICICI, FCF decline at Infosys down 8.1% YoY in INR, credit cost normalisation expectations at Bajaj), with the most material developments being Infosys's guidance revision, ICICI's margin and asset-quality mix, and Bajaj Finance's gold-loan stress. Several filings (Trent IEPF notice, Infosys auditor UDIN filing, Power Grid commissioning) are compliance or operational in nature and carry limited market impact.

4 high priority 10 medium 14 total filings
· daily

India Merger Acquisition MCA Regulatory Filings — October 23, 2026

Across the 24 filings, the dominant theme is corporate restructuring through intra-group amalgamations (Newgen, Heritage Foods, Siemens Rail, Veefin, Cyber Media, Shiva Texfabs/Rudra Ecovation) alongside a wave of small minority stake purchases disclosed under Regulation 30 by ASI Industries, Maithan Alloys, Relaxo and Ashika. The most material capital deployments are JSW Steel's Rs 3,750 crore equity commitment to the JJSL Sambalpur expansion and Sancode's USD 20.2 million Cirtek OSAT acquisition, while Bharat Petroleum's Rs 4,900 crore greenfield refinery vehicle is still subject to approvals. Period-over-period data is mixed: Newgen grew consolidated revenue roughly 18% YoY to Rs 42,223 lakh with net profit rising to Rs 8,688 lakh, but Jupiter Life Line's standalone quarterly net profit fell about 38% YoY even as its half-year figure rose, and Bijnis (Info Edge target) saw turnover fall 14.1% despite Rs 44 crore PAT on a Rs 7.8 crore net worth, which warrants skepticism. Several targets show turnover volatility (ASI's Lloyds Enterprises down ~21.9% in FY26, Lloyds Engineering up ~39% in FY26), so acquirer stake rationale rests on investment intent rather than operating fundamentals. Most filings are procedural milestones (NCLT orders, record dates, effective dates) and therefore carry near-term catalysts with dated execution steps rather than immediate valuation changes.

13 high priority 11 medium 24 total filings
· monthly

India Pre-Market Regulatory Roundup — October 23, 2026

The 50-filing overnight batch (Oct 22-23, 2026) is dominated by routine governance: board-meeting intimations, trading-window closures and earnings-call notices for Q2/H1 FY27, several of which cluster on Oct 27-30 and will form the next catalyst wave. Substantive operating data is concentrated in a handful of filings: Aurum PropTech (Q2 revenue +64% YoY, Housing.com acquisition closed), Orient Electric (revenue +25.2% YoY, EBITDA +49.7%, but gross margin compressed to 29% under input-cost inflation), Fairchem Organics (revenue +49.7% YoY, PBT up sharply but finance cost +83%), and Purple Finance (standalone AUM +101% YoY, consolidated PAT ₹138.59 lakh for H1). The clearest negative is Zee Learn: standalone profit recovered sharply, but consolidated continuing operations remain loss-making, lenders have invoked guarantees totalling ₹81,987 lakh, CIRP petitions are pending before NCLT, and the auditor flagged material going-concern uncertainty. Leading Leasing swung to a half-year pre-tax loss of ₹(1,891.63) lakh from a ₹874.79 lakh profit, with finance costs up roughly 125%. Insider and promoter behaviour is largely unremarkable; the notable governance pattern is institutional dissent on remuneration and appointment resolutions at Dalmia Bharat and TVS Motor, where promoter votes mechanically carried outcomes. Several filings carry internal inconsistencies (Netripples dates, SMC Global quarter labelling, Archean rating direction) that warrant verification before any reliance.

11 high priority 39 medium 50 total filings